Analyst Steven Lichtman works at OPPENHEIMER and is focused on the Healthcare sector with 325 price targets and ratings documented since 2010 spanning on 16 stocks. Analyst's average stock valuation to be materialised ratio is 74.58% with an average time for price targets to be met of 254.93 days.
Most recent stock forecast was given on CFMS, Conformis, Inc at 11-Nov-2022.
Steven Lichtman best performing recommendations are on TNDM (TANDEM DIABETES CARE, INC).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE, INC) at 2/27/2019. The price target of $68 was fulfilled within 2 days with a profit of $6.14 (9.93%) receiving and performance score of 49.63.
Average potential price target upside